Blade Biotherapeutics

Blade Biotherapeutics was a clinical-stage biopharmaceutical company focused on developing novel therapies for debilitating fibrotic and neurodegenerative diseases. The company's pipeline was built on a deep understanding of biological pathways contributing to tissue damage and repair, specifically targeting autotaxin and calpain. Its lead asset, cudetaxestat, is a non-competitive autotaxin inhibitor that was evaluated in Phase 2 clinical trials for idiopathic pulmonary fibrosis. Blade aimed to address significant unmet medical needs through small molecule modulators that could potentially halt or reverse disease progression. However, the company reportedly ceased active operations following a terminated SPAC merger in 2022.